Orthocell Ltd
Orthocell Ltd (ASX:OCC) is listed on the Australian Securities Exchange.
See more information about Orthocell Ltd
Orthocell secures European patent for its tissue regeneration technology
Orthocell Ltd (ASX:OCC) has been granted a European patent for its CelGro® collagen medical device platform for soft tissue regeneration and repair applications.
The patent entitled "Method for Producing a Collagen Membrane and Uses Thereof" provides additional important intellectual property to protect the CelGro product platform.
Orthocell managing director Paul Anderson said: "This is an important addition to our current European and global IP portfolio and further strengthens our IP position.
"This comes at a perfect time for the company as we drive product adoption and sales of CelGro® in Europe."
Patent granted in major global markets
CelGro is manufactured by Orthocell using its proprietary SMRTTM tissue engineering process, developed in conjunction with Professor Minghao Zheng and the University of Western Australia.
The customizable collagen medical device has numerous competitive advantages over existing synthetic and biologic tissue repair devices.
In addition to Europe, CelGro patents are now granted in the US, China, Canada, Singapore, Australia and New Zealand.
Other Orthocell Ltd news
- Orthocell granted key US divisional patent for CelGro®
2021-02-15 - Orthocell shares sharply higher on back of positive results in CelGro® nerve repair clinical study
2020-11-20 - Orthocell submits Australian TGA regulatory application for CelGro® nerve regeneration platform
2020-07-30 - Orthocell's Ortho-ATI™ cell therapy features in respected ISAKOS textbook
2020-05-15 - Orthocell completes US 510(k) submission to FDA for CelGro® bone regeneration product
2020-05-12
